Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac
The ongoing pandemic of coronavirus disease 2019 makes it important to study the immunogenicity, the duration of immune response, and the safety of existing vaccines.Aim. As part of a prospective observational study, to assess associations between levels of anti-Severe Acute Respiratory Syndrome Cor...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2022-07-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839577803619565568 |
|---|---|
| author | O. M. Drapkina S. A. Berns A. Yu. Gorshkov L. N. Ryzhakova A. A. Ivanova A. V. Emelyanov S. N. Voinova R. A. Karateev N. A. Arablinskiy A. A. Rodionova V. S. Bashnyak M. S. Pokrovskaya |
| author_facet | O. M. Drapkina S. A. Berns A. Yu. Gorshkov L. N. Ryzhakova A. A. Ivanova A. V. Emelyanov S. N. Voinova R. A. Karateev N. A. Arablinskiy A. A. Rodionova V. S. Bashnyak M. S. Pokrovskaya |
| author_sort | O. M. Drapkina |
| collection | DOAJ |
| description | The ongoing pandemic of coronavirus disease 2019 makes it important to study the immunogenicity, the duration of immune response, and the safety of existing vaccines.Aim. As part of a prospective observational study, to assess associations between levels of anti-Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) S protein IgG antibodies and thrombodynamics parameters in individuals vaccinated with Gam-COVID-Vac and CoviVac vaccines.Material and methods. The study included 137 people who completed the first 3 visits: 30 people received the Gam-COVID-Vac, 107 people — CoviVac. The study participants underwent venous blood sampling before the introduction of the 1st and 2nd vaccine doses, as well as 42 days after the administration of 1st dose in order to quantify the level of IgG antibodies. At each visit, plasma hemostasis parameters were analyzed using a thrombodynamics test.Results. During the follow-up period, there was a clear increase in the level of anti-SARS-CoV-2 S protein IgG antibodies in both groups. At the same time, this increase over time was significantly greater in Gam-COVID-Vac group. There was no correlation detected between thrombodynamics test results and the levels of anti-SARS-CoV-2 S protein IgG antibodies.Conclusion. The data obtained demonstrate the ability of both vaccines to stimulate the production of anti-SARS-CoV-2 antibodies. However, immune response to Gam-COVID-Vac is much higher. The lack of correlation between thrombodynamics and the level of specific antibodies suggests that vaccination for COVID-19 with Gam-COVIDVac and CoviVac does not cause changes in plasma hemostasis and does not increase the risk of thrombosis. |
| format | Article |
| id | doaj-art-bcf3bb29b4b34eeaa2e104dbbe01cf6d |
| institution | Matheson Library |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2022-07-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-bcf3bb29b4b34eeaa2e104dbbe01cf6d2025-08-04T12:50:28Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252022-07-0121610.15829/1728-8800-2022-32952487Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVacO. M. Drapkina0S. A. Berns1A. Yu. Gorshkov2L. N. Ryzhakova3A. A. Ivanova4A. V. Emelyanov5S. N. Voinova6R. A. Karateev7N. A. Arablinskiy8A. A. Rodionova9V. S. Bashnyak10M. S. Pokrovskaya11National Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineA.I. Evdokimov Moscow State University of Medicine and DentistryNational Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineThe ongoing pandemic of coronavirus disease 2019 makes it important to study the immunogenicity, the duration of immune response, and the safety of existing vaccines.Aim. As part of a prospective observational study, to assess associations between levels of anti-Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) S protein IgG antibodies and thrombodynamics parameters in individuals vaccinated with Gam-COVID-Vac and CoviVac vaccines.Material and methods. The study included 137 people who completed the first 3 visits: 30 people received the Gam-COVID-Vac, 107 people — CoviVac. The study participants underwent venous blood sampling before the introduction of the 1st and 2nd vaccine doses, as well as 42 days after the administration of 1st dose in order to quantify the level of IgG antibodies. At each visit, plasma hemostasis parameters were analyzed using a thrombodynamics test.Results. During the follow-up period, there was a clear increase in the level of anti-SARS-CoV-2 S protein IgG antibodies in both groups. At the same time, this increase over time was significantly greater in Gam-COVID-Vac group. There was no correlation detected between thrombodynamics test results and the levels of anti-SARS-CoV-2 S protein IgG antibodies.Conclusion. The data obtained demonstrate the ability of both vaccines to stimulate the production of anti-SARS-CoV-2 antibodies. However, immune response to Gam-COVID-Vac is much higher. The lack of correlation between thrombodynamics and the level of specific antibodies suggests that vaccination for COVID-19 with Gam-COVIDVac and CoviVac does not cause changes in plasma hemostasis and does not increase the risk of thrombosis.https://cardiovascular.elpub.ru/jour/article/view/3295vaccinationcoronavirus infectioncovid-19gam-covidvaccovivacanti-sars-cov-2 igg antibodiesthrombodynamics |
| spellingShingle | O. M. Drapkina S. A. Berns A. Yu. Gorshkov L. N. Ryzhakova A. A. Ivanova A. V. Emelyanov S. N. Voinova R. A. Karateev N. A. Arablinskiy A. A. Rodionova V. S. Bashnyak M. S. Pokrovskaya Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac Кардиоваскулярная терапия и профилактика vaccination coronavirus infection covid-19 gam-covidvac covivac anti-sars-cov-2 igg antibodies thrombodynamics |
| title | Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac |
| title_full | Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac |
| title_fullStr | Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac |
| title_full_unstemmed | Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac |
| title_short | Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac |
| title_sort | association of humoral immunity status and thrombodynamics after vaccination with gam covid vac and covivac |
| topic | vaccination coronavirus infection covid-19 gam-covidvac covivac anti-sars-cov-2 igg antibodies thrombodynamics |
| url | https://cardiovascular.elpub.ru/jour/article/view/3295 |
| work_keys_str_mv | AT omdrapkina associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT saberns associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT ayugorshkov associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT lnryzhakova associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT aaivanova associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT avemelyanov associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT snvoinova associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT rakarateev associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT naarablinskiy associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT aarodionova associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT vsbashnyak associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac AT mspokrovskaya associationofhumoralimmunitystatusandthrombodynamicsaftervaccinationwithgamcovidvacandcovivac |